Dosing Initiation, Conferences Participation, Trial Results Publication, and Financial Results - Analyst Notes on Arena, Acceleron Pharma, HealthSouth, The Medicines Company and Taro

NEW YORK, June 10, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Acceleron Pharma Inc. (NASDAQ: XLRN), HealthSouth Corporation (NYSE: HLS), The Medicines Company (NASDAQ: MDCO) and Taro Pharmaceutical Industries Ltd. (NYSE: TARO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3548-100free.

--
Arena Pharmaceuticals, Inc. Analyst Notes
On June 3, 2014, Arena Pharmaceuticals, Inc. (Arena) initiated dosing in an investigational Phase 1b clinical trial of APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor to evaluate the compound for treatment of a number of autoimmune diseases such as multiple sclerosis, psoriasis, and rheumatoid arthritis. The Company state that this randomized, double-blind and placebo-controlled trial will evaluate the safety, tolerability, and pharmacokinetics of multiple-ascending doses of APD334 in up to 96 adult volunteers. William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer, said, "We continue to make progress in advancing our novel pipeline of internally discovered drug candidates, and remain committed to our vision of leading the industry in the discovery, development and commercialization of GPCR-directed medicines." The full analyst notes on Arena are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/ARNA/report.pdf

--
Acceleron Pharma Inc. Analyst Notes
On May 29, 2014, Acceleron Pharma Inc. (Acceleron Pharma) announced that it will provide corporate presentations in three upcoming investor conferences. Acceleron Pharma will present at Goldman Sachs 35th Annual Global Healthcare Conference on June 10, 2014 at 4:00 PM PDT. On June 16, 2014, the Company will participate at the European Hematology Association (EHA) Conference Call and Data Review at 8:00 a.m. EDT. The Company will host a conference call and webcast to review data presented at the European Hematology Association's annual meeting. On June 17, 2014, it will participate at the Wells Fargo Securities 2014 Healthcare Conference in Boston, Massachusetts, at 8:15 a.m. EDT. A live audio webcast of each presentation, as well as its replay, will be made available on the Investors & Media section of the Company website. The full analyst notes on Acceleron Pharma are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/XLRN/report.pdf

--
HealthSouth Corporation Analyst Notes
On June 3, 2014, HealthSouth Corporation (HealthSouth) announced its participation in the 2014 Wells Fargo Securities Healthcare Conference on June 17-18, 2014 in Boston. Jay Grinney, HealthSouth President and CEO, will participate in a fireside chat presentation on June 18, 2014, at 10:40 a.m. ET. The presentation will webcast live and can be accessed on the Company's Investor Relations website. The full analyst notes on HealthSouth are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/HLS/report.pdf

--
The Medicines Company Analyst Notes
On June 5, 2014, The Medicines Company announced that the results from the SOLO I Phase 3 clinical trial of ORBACTIVTM (oritavancin), an investigational intravenous antibiotic treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), have been published in the New England Journal of Medicine. According to the Company, the publication reported that a single 1200 mg intravenous dose of ORBACTIVTM was non-inferior to twice-daily intravenous dosing of vancomycin given for 7-10 days in patients afflicted with ABSSSI caused or suspected to be caused by Gram-positive bacteria. Matthew Wikler, MD, Vice President, Infectious Disease Care at The Medicines Company, said, "Our work with the SOLO trials is the first in a series of major clinical trials that we are undertaking in the quest to take on difficult-to-treat infections - sometimes caused by so-called "superbugs" in patients in potentially life-threatening situations requiring admission and care in the hospital." The full analyst notes on The Medicines Company are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/MDCO/report.pdf

--
Taro Pharmaceutical Industries Ltd. Analyst Notes
On May 27, 2014, Taro Pharmaceutical Industries Ltd. (Taro) reported its Q4 FY 2014 and FY 2014 financial results (period ended March 31, 2014). Q4 FY 2014 net sales increased 13.3% YoY to $187.2 million, while FY 2014 net sales increased 13.2% YoY to $759.3 million. Q4 FY 2014 net income attributable to the Company was $89.6 million, or $2.10 per diluted share, compared with $49.2 million, or $1.10 per diluted share in Q4 FY 2013. Meanwhile, FY 2014 net income attributable to the Company came in at $360.4 million, or $8.14 per diluted share, compared with $266.2 million, or $5.95 per diluted share in FY 2013. The full analyst notes on Taro are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/TARO/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED